According to the IVW results, ANGPTL3 inhibitors were significantly associated with a reduced risk of CKD in the CKDGen database (OR [95% CI] = 0.826 [0.714, 0.955], p = 0.010). This evidence concerns the gene ANGPTL3 and chronic kidney disease.